Fate stock: buy or sell?

FATE stock price: $35.23 5.04% At close on May 22nd, 2020

Updated on:
May 22nd, 2020


After climbing to all-time highs several times in past weeks, Fate boosted 5.04% to $35.23. On Thursday FATE skyrocketed an astounding 7.60%. May 22nd was the third green day in a row, gaining 21.52%.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.

Should I buy Fate stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

Currently, 2 buy setups match with Fate Therapeutics stock right now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is Fate stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't detect any rating for FATE stock for the last 30 days.

Fate stock analysis

Daily outlook

After climbing to all-time highs several times in past weeks, Fate boosted 5.04% to $35.23.

After several days of continuous rises in past weeks, Fate boosted 5.04% to $35.23. On March FATE price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. Since last February when SMA100d and SMA200d crossed up, FATE price gained $5.87 per share (19.99%). On May 22nd, FATE hit a new all time high, pushing higher than on Thursday tops. Check different trading setups that use ATHs as triggers.

FATE stock chart (daily)

Weekly outlook

Fate Therapeutics shares climbed 23.83% this week and reached a new all time high at $35.25. Late April FATE collapsed a hair-raising -15.53% in just one week.

If you observe the weekly chart, price finally broke over the resistance at $32.00 and continued climbing. By mid February, SMA20w and SMA40w crossed up triggering a rise of 21.99%. Since early December 2019 when FATE stock price broke up the SMA40w line, it gained $21.56 (157.72%).

FATE stock chart (weekly)

Fate stock price history

Fate stock went public on October 1st, 2013 with a price of $6.561. Since then, FATE stock surged a 437.00%, with an average of 72.80% per year. If you had invested $1,000 in Fate stock in 2013, it would worth $4,370.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Fate stock historical price chart

FATE stock reached all-time highs on May/22 with a price of $35.25.

Fate stock price target

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we have not found any price prediction for Fate Therapeutics stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

, Fate presented its financial report, posting a tiny gain for the Earnings per Share (EPS) ratio. Experts expected $-0.24 per share, but Fate posted $-0.25.
FATE earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual sales report draw an amazing increase of 15.44% to $4.74 M USD. Instead, its income margin (compared to sales) collapsed to -1,405.02%, that is $-66.60 million.

FATE annual Sales and Income evolution
2013$0.97 M-$-20.89 M-2151.4%-
2015$2.43 M150.36%$-29.99 M-1233.7%43.57%
2016$4.40 M81.08%$-33.46 M-760.2%11.57%
2017$4.11 M-6.72%$-42.95 M-1046.1%28.36%
2018$4.74 M15.44%$-66.60 M-1405.0%55.05%

Quarterly financial results

Fate Therapeutics reported $1.66 M in sales for 2018-Q4, a 61.89% up compared to previous quarter. Reported quarter income marked $-16.03 million with a profit margin of -964.90%. Profit margin rocketed a 670.77% compared to previous quarter when profit margin was -1,635.67%. When comparing sales to same quarter last year, Fate sales marked an astounding gain and skyrocketed a 61.73%.
FATE quarterly Sales and Income evolution
2017-Q1$1.03 M-$-10.13 M-983.5%-
2017-Q2$1.03 M0.00%$-9.65 M-936.9%-4.74%
2017-Q3$1.03 M0.00%$-10.68 M-1036.9%10.67%
2017-Q4$1.03 M-0.29%$-12.50 M-1216.8%17.01%
2018-Q1$1.03 M-0.10%$-14.14 M-1377.7%13.11%
2018-Q2$1.03 M0.10%$-19.65 M-1913.7%39.04%
2018-Q3$1.03 M-0.10%$-16.78 M-1635.7%-14.61%
2018-Q4$1.66 M61.89%$-16.03 M-964.9%-4.50%

Fate ownership

Checking Fate Therapeutics ownership structure gives valuable information about the company and its governance (insider ownership) or the amount of investors that are on the short side.

Fate shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 2.07% of all shares.

Bearish positions for FATE stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Fate:

Market cap$2.7 B
Total shares77.7 M
Float shares65.4 M
  - Institutional holdings (%)94.7%
  - Insider holdings (%)2.1%
Shares in short selling0.0%

Fate summary

Friday, May 22nd, 2020
Day range$32.12 - $35.25
Previous close$33.54
Session gain5.04%
Average true range$2.41
50d mov avg$26.66
100d mov avg$26.30
200d mov avg$21.39
Daily pattern
Weekly pattern lb01c

Fate performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We compared Fate Therapeutics against in the following table:
FATEFate Therapeutics13.87%144.82%85.71%

Fate competitors

Unfortunately, we could not find any public company that could be defined as Fate competitor. This doesn't mean Fate does not have any competitor in the market, it's just we could not detected it.